Argenx gets FDA approval for Vyvgart Hytrulo for CIPD (NASDAQ:ARGX)
2024-06-21
Waldemarus/iStock via Getty Images Argenx (NASDAQ:ARGX) has received FDA approval for Vyvgart Hytrulo for the treatment of adults with chronic inflammatory demyelinating polyneuropathy, or CIDP. The Dutch biotech company said the product was the first and only neonatal Fc receptor blocker approved to treat the condition. Vyvgart Hytrulo is alsoContinue Reading